April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
21 citations
,
August 1994 in “Clinical endocrinology” 5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
9 citations
,
February 1996 in “Lancet” Some tuberculosis drugs may cause hair loss, but hair might regrow after treatment or changing the drugs.
70 citations
,
August 2019 in “European Journal of Medicinal Chemistry”
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
2 citations
,
January 2011 in “Andrologia” Flutamide and a new synthetic steroid affected brain and prostate chemicals and showed potential for treating androgen-related conditions and epilepsy.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
20 citations
,
April 2019 in “BioMed Research International” Treatments with sunscreen and active ingredients can reduce skin hyperpigmentation by decreasing DNA methylation.